Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

e, monitoring of growth in children taking GLEEVEC is recommended.

Cases of tumor lysis syndrome (TLS), including fatal cases, have been reported. The patients at risk of TLS are those with tumors having a high proliferative rate or high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

In Ph+ CML trials(****), severe (NCI Grades 3/4) lab abnormalities—including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia (<1%-33%), and hepatotoxicity (approx 5%)—and severe adverse experiences (NCI Grades 3/4), including hemorrhage (1.8%-19%), fluid retention (eg, pleural effusion, pulmonary edema, and ascites) (2.5%-11%) and superficial edema (1.5%-6%), and musculoskeletal pain (2%-9%), were reported among patients receiving GLEEVEC. Severe fluid retention appears to be dose-related, was more common in the advanced phase studies (where the dosage was 600 mg/day), and is more common in the elderly.

There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and gastrointestinal (GI) perforation.

GLEEVEC is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Significant reductions in imatinib concentrations may occur when GLEEVEC is administered concomitantly with agents that are strong CYP3A4 inducers such as rifampin, St. John's wort, and enzyme-inducing anti-epileptic drugs, eg, phenytoin. The use of concomitant strong CYP3A4 inducers should be avoided. If patients must be administered a strong CYP3A4 inducer, the dosage of GLEEVEC should be increased by at least 50% and clinical response should be carefully monitored. Caution is recommended when GLEEVEC is administered with CYP3A4 inhibitors such as ketoconazole, with CYP2D6 substrates that have a narrow therapeutic window, or with CYP3A4 substrates that have a narrow therapeutic window. Other examples of commonly used drug
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 According to a new ... by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), ... CRO) - Global Forecast to 2020", published by MarketsandMarkets, the ... 2020 from $107.56 Million in 2015, at a CAGR of ... and 67 F igures spread through 125 ...
(Date:6/29/2015)... NEW YORK , June 29, 2015   For ... of life sciences to assess their overall digital maturity ... to show that these companies are not maturing fast ... the healthcare industry in numerous ways overall and customers ... industries in terms of digital customer engagement.  ...
(Date:6/26/2015)... , June 26, 2015   ... ), a pet therapeutics company focused on ... biopharmaceutical products for companion animals, today announced ... study of capromorelin (AT-002), the company,s innovative ... is a small molecule that mimics ghrelin, ...
(Date:6/26/2015)...  A San Francisco company, Pembient, recently announced it ... horn: beer in China and ... response to the emerging industry, two leading rhino conservation ... synthetic rhino horn.  The International ... International (SRI) released a joint statement ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.506 12/2001 , , ... , , , Microorganism , ... Cell type , Bacteria, gram negative, ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , Multiporator / Electroporator 2510 , , , , , , ... Protocol , Protocol No. 4308 915.502 12/2001 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, , ...
Cached Biology Technology:Borrelia burgdorferi 2Bifidobacterium animalis 2Agrobacterium tumefaciens 2
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... the Southern Ocean, large quantities of surface-drifting plankton algae are ... surface waters, which can affect the global carbon dioxide cycle. ... which has just drawn to a close in Cape Town ... Wegener Institute, part of the Helmholtz Association. On February 5, ...
... Rochet, a research scientist at IFREMER (The French Research ... the prestigious Pew Fellowship in Marine Conservation to determine ... to the delicately balanced marine ecosystem. She will use ... use of that technique, and to further improve its ...
... YORK CITY - Dr. Ussif Rashid Sumaila, an Associate ... in Vancouver, Canada, is among five ocean experts to ... Conservation, which supports critical marine conservation projects around the ... the financial factors contributing to unsustainable commercial fishing and ...
Cached Biology News:Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 2Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 3Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 42008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 22008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 32008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 42008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 22008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 32008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 4
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: